ProCE Banner Activity

Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

Podcast Episodes
Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.

Released: May 04, 2021

Expiration: May 03, 2022

No longer available for credit.

Share

Faculty

Ignacio Duran

Ignacio Duran, MD, PhD

Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Alison Birtle

Alison Birtle, MD, FRCP, FRCR

Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Program Director Disclosure

Program Director

Ignacio Duran, MD, PhD

Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Faculty Disclosure

Primary Author

Alison Birtle, MD, FRCP, FRCR

Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom

Ignacio Duran, MD, PhD

Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain